press releases

More than 204 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that Health Care Service Corporation (HCSC) will cover Optune for members who have newly diagnosed glioblastoma (GBM) effective… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in the JMP Securities 2017 Life Sciences Conference on June 21, 2017, in New York. Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, will speak on behalf of the company and address… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in the JMP Securities 2017 Life Sciences Conference on June 21, 2017, in New York. Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, will speak on behalf of the company and address… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that United States Food and Drug Administration (FDA) has designated it’s Tumor Treating Fields (TTFields) delivery system as a Humanitarian Use Device (HUD) for the treatment of pleural mesothelioma. HUD designation covers devices that treat rare, orphan diseases or… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that United States Food and Drug Administration (FDA) has designated it’s Tumor Treating Fields (TTFields) delivery system as a Humanitarian Use Device (HUD) for the treatment of pleural mesothelioma. HUD designation covers devices that treat rare, orphan diseases or… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced that Martin J. Madden, a longtime leader in the medical device industry, was elected to its Boards of Directors during Novocure’s 2017 annual general meeting of shareholders. In addition, Mr. Madden has been appointed to Novocure’s Audit and Nominating and Corporate… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced that Martin J. Madden, a longtime leader in the medical device industry, was elected to its Boards of Directors during Novocure’s 2017 annual general meeting of shareholders. In addition, Mr. Madden has been appointed to Novocure’s Audit and Nominating and Corporate… Read More

Addition of Optune to temozolomide did not negatively impact quality of life for newly diagnosed glioblastoma patients except for causing itchy skin ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure™ (NASDAQ:NVCR) announced today results from health-related quality of life analyses from its phase 3, pivotal EF-14 trial adding… Read More

Trials sponsored by the Pediatric Brain Tumor Consortium and Hackensack University Medical Center now open and recruiting ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today two pilot trials are open and actively recruiting pediatric patients with high grade gliomas to evaluate the safety and feasibility of Tumor… Read More